In this episode of The Retina Channel Podcast, I sit down with Dr. Seong Joon Ahn from Hanyang University in South Korea to discuss a recent JAMA Ophthalmology study examining systemic drugs associated with underrecognized maculopathy. Using a novel two-step approach that integrates pharmacovigilance signal detection from the FDA Adverse Event Reporting System (FAERS) with nationwide health-claims data from South Korea, the study identifies several commonly used systemic medications— apixaban, paclitaxel, ibrutinib, fingolimod, and sildenafil—as being associated with an increased risk of maculopathy. We explore the study's methodology, key findings such as dose-response relationships, and the clinical implications for retina specialists and general ophthalmologists alike, particularly around patient counseling and the potential need for ocular monitoring in patients on these medications.
Kim J, Ahn SJ, Park J, Gower EW, Chung JE. Systemic drugs associated with maculopathy. JAMA Ophthalmol.2025;143(11):946-952. doi:10.1001/jamaophthalmol.2025.3612.
